AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24244090 — intervention group
Group type: COMPARATOR
Intervention: Aerobic/resistance training (control)
Number of subjects: 34
Study 24245549 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib & Ursodeoxycholic acid (UDCA), n = 14
Number of subjects: 37
Study 24245549 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib & Placebo, n = 13
Number of subjects: 37
Study 24245549 — intervention group
Group type: COMPARATOR
Intervention: Normal appearing mucosa of patients with FAP
Number of subjects: 37
Study 24245549 — intervention group
Group type: COMPARATOR
Intervention: Non-FAP patient controls, n = 16
Number of subjects: 37
Study 24246044 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 4427
Study 24246044 — intervention group
Group type: EXPERIMENTAL
Intervention: OAB-5D
Number of subjects: 4427
Study 24246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel (15 mg/m² IV) with timed thoracic radiotherapy (TTR) (total 55 Gy) followed by adjuvant chemotherapy (carboplatin AUC 5 on day 1, gemcitabine 1000 mg/m² on days 1 and 8, every 21 days for 4 cycles)
Number of subjects: 27
Study 24246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose paclitaxel with concurrent TTR
Number of subjects: 27
Study 24246506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine/carboplatin
Number of subjects: 27
Study 24246622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuss procedure
Number of subjects: 327
Study 24246704 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg orally per day, with dose escalation by 25mg every two weeks until grade 2/tolerable rash or other dose limiting toxicity developed.
Number of subjects: 137
Study 24246704 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib dose escalation to the development of grade 2 skin rash.
Number of subjects: 137
Study 24246704 — intervention group
Group type: COMPARATOR
Intervention: Comparison to first-line chemotherapy.
Number of subjects: 137
Study 24246789 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Pain Medicine Questionnaire
Number of subjects: 0
Study 24247327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (<75 nmol/L)
Number of subjects: 677
Study 24247327 — intervention group
Group type: EXPERIMENTAL
Intervention: Each unit higher 25-hydroxyvitamin D levels at baseline
Number of subjects: 677
Study 24247327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 677
Study 24247327 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 677
Study 24247415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary stem cell delivery
Number of subjects: 0
Study 24247415 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24248178 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels measured in winter
Number of subjects: 314
Study 24248178 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels measured in spring and summer
Number of subjects: 314
Study 24248178 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sclerostin levels measured in fall
Number of subjects: 314
Study 24248942 — intervention group
Group type: EXPERIMENTAL
Intervention: Very large HDL subclasses
Number of subjects: 26332
Study 24248942 — intervention group
Group type: EXPERIMENTAL
Intervention: Large HDL subclasses
Number of subjects: 26332
Study 24248942 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium HDL subclasses
Number of subjects: 26332
Study 24248942 — intervention group
Group type: EXPERIMENTAL
Intervention: Small HDL subclasses
Number of subjects: 26332
Study 24248942 — intervention group
Group type: EXPERIMENTAL
Intervention: Very small HDL subclasses
Number of subjects: 26332
Study 24249049 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment
Number of subjects: 935
Study 24249802 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) assessments using Teller acuity cards as the primary endpoint.
Number of subjects: 0
Study 24249802 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity (VA) assessments using HOTV as a secondary endpoint.
Number of subjects: 0
Study 24249802 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of optic disc for pallor.
Number of subjects: 0
Study 24249802 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of visual quality of life using the Children's Visual Function Questionnaire.
Number of subjects: 0
Study 24249967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 24249967 — intervention group
Group type: EXPERIMENTAL
Intervention: RESMENA group
Number of subjects: 46
Study 24249967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary strategies
Number of subjects: 46
Study 24249967 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SERPINE1 methylation levels at baseline
Number of subjects: 46
Study 24251951 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (HOMA-IR >4)
Number of subjects: 22
Study 24251951 — intervention group
Group type: COMPARATOR
Intervention: Insulin-sensitive group (HOMA-IR ≤ 4)
Number of subjects: 22
Study 24252049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with concomitant use of methotrexate (MTX)
Number of subjects: 7740
Study 24252049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 7740
Study 24252049 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 7740
Study 24252402 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 (60 mg QOD schedule)
Number of subjects: 34
Study 24252402 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 (135 mg QW schedule)
Number of subjects: 34
Study 24252402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MK-2206 and trastuzumab
Number of subjects: 34
Study 24252402 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 34
Study 24253138 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended heparin prophylaxis (4 weeks)
Number of subjects: 225
Study 24253138 — intervention group
Group type: COMPARATOR
Intervention: Short heparin prophylaxis (1 week)
Number of subjects: 225
Study 24253138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 225
Study 24254708 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting absorbable metal scaffold
Number of subjects: 46
Study 24254965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 40
Study 24255769 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent.
Number of subjects: 133
Study 24255769 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS surgical approach
Number of subjects: 133
Study 24255769 — intervention group
Group type: COMPARATOR
Intervention: Open thoracotomy surgical approach
Number of subjects: 133
Study 24255769 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen
Number of subjects: 133
Study 24256329 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rate brachytherapy
Number of subjects: 604
Study 24257381 — intervention group
Group type: EXPERIMENTAL
Intervention: AnaConDa® (ACD)
Number of subjects: 6
Study 24257381 — intervention group
Group type: COMPARATOR
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 6
Study 24257514 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw vegetable intake (68 g per 1000 kcal)
Number of subjects: 2195
Study 24257514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked vegetable intake (92 g per 1000 kcal)
Number of subjects: 2195
Study 24258465 — intervention group
Group type: EXPERIMENTAL
Intervention: E7107 at 5.7 mg/m(2)
Number of subjects: 26
Study 24258465 — intervention group
Group type: EXPERIMENTAL
Intervention: E7107 at 4.3 mg/m(2)
Number of subjects: 26
Study 24258465 — intervention group
Group type: EXPERIMENTAL
Intervention: E7107 (various doses)
Number of subjects: 26
Study 24258465 — intervention group
Group type: EXPERIMENTAL
Intervention: E7107 (3.2 mg/m(2) and 4.3 mg/m(2))
Number of subjects: 26
Study 24258465 — intervention group
Group type: EXPERIMENTAL
Intervention: E7107
Number of subjects: 26
Study 24259241 — intervention group
Group type: COMPARATOR
Intervention: Cesarean delivery
Number of subjects: 129
Study 24259241 — intervention group
Group type: COMPARATOR
Intervention: Respiratory support
Number of subjects: 129
Study 24259241 — intervention group
Group type: EXPERIMENTAL
Intervention: Study population
Number of subjects: 129
Study 24259241 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 129
Study 24259445 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO PCI
Number of subjects: 3303
Study 24259445 — intervention group
Group type: COMPARATOR
Intervention: Non-CTO PCI
Number of subjects: 3303
Study 24260259 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 subgenotype C4 vaccines
Number of subjects: 119
Study 24260259 — intervention group
Group type: COMPARATOR
Intervention: Sera from pediatric patients recovering from EV71-induced HFMD
Number of subjects: 119
Study 24260259 — intervention group
Group type: COMPARATOR
Intervention: Sera from subclinically infected participants
Number of subjects: 119
Study 24261337 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit of strategies for non-clinician panel management assistants (PMAs) to enhance panel-wide outcomes in smoking cessation and hypertension.
Number of subjects: 0
Study 24261337 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit strategies grouped into 5 areas: continuous connection to care, education and connection to clinical resources, targeted behavior change counseling, adherence support, and patients with special needs.
Number of subjects: 0
Study 24261605 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase inhibitors (CEIs)
Number of subjects: 120
Study 24261605 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 120
Study 24261605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-dementia drugs)
Number of subjects: 120
Study 24261996 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1 administered intranasally before RSV infection
Number of subjects: 0
Study 24261996 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1 administered neonatally
Number of subjects: 0
Study 24261996 — intervention group
Group type: EXPERIMENTAL
Intervention: BPZE1
Number of subjects: 0
Study 24261996 — intervention group
Group type: COMPARATOR
Intervention: Anti-IL-17 antibodies
Number of subjects: 0
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures performed (chest tube removal, wound drain removal, arterial line insertion)
Number of subjects: 3851
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid administration specifically for the procedure
Number of subjects: 3851
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural pain intensity
Number of subjects: 3851
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural pain distress
Number of subjects: 3851
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of the worst pain on the same day, before the procedure
Number of subjects: 3851
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure not performed by a nurse
Number of subjects: 3851
Study 24262016 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedural pain intensity
Number of subjects: 3851
Study 24262504 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine neutrophil gelatinase-associated lipocalin (uNGAL) measured within 24 hours of bypass, normalized to creatinine.
Number of subjects: 200
Study 24262504 — intervention group
Group type: EXPERIMENTAL
Intervention: uNGAL levels measured at various time points post-surgery.
Number of subjects: 200
Study 24262504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clusterization algorithm applied to uNGAL kinetics.
Number of subjects: 200
Study 24262504 — intervention group
Group type: EXPERIMENTAL
Intervention: Number needed to screen (NNS) to identify risk of dialysis or death.
Number of subjects: 200
Study 24263064 — intervention group
Group type: EXPERIMENTAL
Intervention: gefitinib 250 mg day(-1) until progression
Number of subjects: 106
Study 24263116 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal multisite left ventricular pacing (MSLV) configuration
Number of subjects: 52
Study 24263116 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 1 MSLV configuration
Number of subjects: 52
Study 24263116 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal MSLV configuration
Number of subjects: 52
Study 24263462 — intervention group
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa (60 U/kg for treatment-naïve patients; 15-60 U/kg for previously treated patients)
Number of subjects: 211
Study 24264034 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.45%, 4 times daily, for 3 days before surgery
Number of subjects: 24
Study 24264034 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 24
Study 24264034 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.45%
Number of subjects: 24
Study 24264395 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes control interventions, specific details not available
Number of subjects: 0
Study 24264395 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study 24265000 — intervention group
Group type: EXPERIMENTAL
Intervention: M-mode echocardiography
Number of subjects: 169
Study 24265000 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D echocardiography
Number of subjects: 169
Study 24265000 — intervention group
Group type: COMPARATOR
Intervention: M-mode or 2D echocardiography
Number of subjects: 169
Study 24265370 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia for ten nights
Number of subjects: 0
Study 24265415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet with weight loss (MedDiet-WL)
Number of subjects: 19
Study 24265415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet without weight loss (MedDiet+WL)
Number of subjects: 19
Study 24265415 — intervention group
Group type: COMPARATOR
Intervention: North American isoenergetic control diet
Number of subjects: 19
Study 24265670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (preventive treatment for 25 days starting one day before myosin immunization)
Number of subjects: 0
Study 24265670 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin (curative treatment for 10 days following the last myosin immunization)
Number of subjects: 0
Study 24265828 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 0
Study 24265828 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab
Number of subjects: 0
Study 24267310 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel medical therapies for pulmonary arterial hypertension
Number of subjects: 0
Study 24267361 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the expiratory flow-volume curve (Aex) measurement during exercise treadmill challenge (ETC)
Number of subjects: 221
Study 24267370 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24267809 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion therapy
Number of subjects: 773
Study 24268114 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed FFR (FFRCT)
Number of subjects: 270
Study 24268114 — intervention group
Group type: COMPARATOR
Intervention: Coronary CTA
Number of subjects: 270
Study 24268114 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 270
Study 24268213 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive imaging and assessment for cardiovascular risk factors, including lifestyle and psychosocial factors.
Number of subjects: 4000
Study 24268213 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-fluorodeoxyglucose-positron emission tomography/magnetic resonance imaging ((18)FDG PET/MRI) study of carotid and iliofemoral arteries in a subgroup of 1300 participants.
Number of subjects: 4000
Study 24268517 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements obtained by independent observers reviewing preoperative CT scans.
Number of subjects: 268
Study 24268517 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements obtained by investigators (extent of aneurysm, target vessel stenosis, and aortic diameters).
Number of subjects: 268
Study 24268517 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements obtained from manufacturers (proximal landing zone, device diameter, and target vessel position).
Number of subjects: 268
Study 24268517 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical discrepancies found in measurements.
Number of subjects: 268
Study 24268783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme intake after 2 hours during continuous feeding for 6 hours.
Number of subjects: 19
Study 24268783 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group).
Number of subjects: 19
Study 24268783 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of whole-body citrulline production rate.
Number of subjects: 19
Study 24269266 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Mountain Sickness (CMS) patients
Number of subjects: 46
Study 24269266 — intervention group
Group type: COMPARATOR
Intervention: Healthy high-altitude (HA) dwellers
Number of subjects: 46
Study 24269855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 56
Study 24269855 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 56
Study 24270505 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers started during hospital admission for myocardial infarction
Number of subjects: 1063
Study 24270505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients already taking β blockers before myocardial infarction
Number of subjects: 1063
Study 24270505 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers started during hospital admission for myocardial infarction (follow-up from discharge)
Number of subjects: 1063
Study 24271095 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical diaphragmatic stimulation (TEDS)
Number of subjects: 15
Study 24273046 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine over 24 weeks
Number of subjects: 1495
Study 24273046 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel followed by capecitabine over 36 weeks
Number of subjects: 1495
Study 24273046 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab-treated patients with HER2-positive disease
Number of subjects: 1495
Study 24273046 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy alone (HER2-negative disease)
Number of subjects: 1495
Study 24273135 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin (40 mg/m² on day 1), vincristine (2 mg on day 1), dexamethasone (40 mg on days 1-4), lenalidomide (10 mg on days 1-21 of every 28-day cycle) followed by lenalidomide maintenance therapy.
Number of subjects: 76
Study 24273135 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy (at last tolerated dose until progression, with or without 50 mg prednisone every other day).
Number of subjects: 76
Study 24273135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with refractory disease.
Number of subjects: 76
Study 24273135 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (combination of drugs mentioned).
Number of subjects: 76
Study 24273135 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (combination of drugs mentioned).
Number of subjects: 76
Study 24273151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 10 mg/m² once daily
Number of subjects: 23
Study 24273151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 40 mg/m² once daily
Number of subjects: 23
Study 24273151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine 80 mg/m² four times daily
Number of subjects: 23
Study 24273151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox olamine (various doses)
Number of subjects: 23
Study 24273174 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A (in groups B and D)
Number of subjects: 0
Study 24273174 — intervention group
Group type: COMPARATOR
Intervention: BCG (in groups A and C)
Number of subjects: 0
Study 24273174 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 0
Study 24273570 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antiepileptic drugs (AEDs) in monotherapy or combination (24.6% of patients)
Number of subjects: 309
Study 24273570 — intervention group
Group type: COMPARATOR
Intervention: Older antiepileptic drugs (AEDs) or combination of older and newer AEDs (75.4% of patients)
Number of subjects: 309
Study 24273570 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment modifications
Number of subjects: 309
Study 24274034 — intervention group
Group type: EXPERIMENTAL
Intervention: Autism (AUT)
Number of subjects: 244
Study 24274034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pervasive developmental disorder not otherwise specified (PDD-NOS)
Number of subjects: 244
Study 24274034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspectrum developmental delays
Number of subjects: 244
Study 24274034 — intervention group
Group type: COMPARATOR
Intervention: Typical development (TD)
Number of subjects: 244
Study 24274658 — intervention group
Group type: EXPERIMENTAL
Intervention: NTM lung disease patients
Number of subjects: 84
Study 24275120 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 0
Study 24275120 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized approach to maintain body iron
Number of subjects: 0
Study 24275629 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemia index (RHI) measured before coronary angiography
Number of subjects: 528
Study 24275629 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 528
Study 24275629 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAXsc
Number of subjects: 528